Literature summary for 3.4.24.87 extracted from

Bresin, E.; Gastoldi, S.; Daina, E.; Belotti, D.; Pogliani, E.; Perseghin, P.; Scalzulli, P.R.; Paolini, R.; Marceno, R.; Remuzzi, G.; Galbusera, M.
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies (2009), Thromb. Haemost., 101, 233-238.

Search for more literature for 3.4.24.87

Activating Compound

Activating Compound	Comment	Organism	Structure
additional information	inhibition of ADAMTS13 by auto-antibodies is reversed by rituximab, overview	Homo sapiens

Localization

Localization	Comment	Organism	GeneOntology No.	Textmining
extracellular	-	Homo sapiens	-	-

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
plasma	-	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
ADAMTS13	-	Homo sapiens

General Information

General Information	Comment	Organism
additional information	ADAMTS13 deficiency, due to existence of auto-antibodies against ADAMTS13, is involved in the severe disease thrombotic thrombocytopenic purpurea, TTP, characterized by thrombocytopenia, microangiopathic hemolytic anemia, and neurological and renal involvement, phenotypes, overview. Inhibition of ADAMTS13 by auto-antibodies is reversed by rituximab, overview	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)